Wedbush reiterated their positive rating on shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) in a research note released on Tuesday morning, The Fly reports. Wedbush currently has a $31.00 price objective on the stock, down from their prior price objective of $36.00. Wedbush also issued estimates for Voyager Therapeutics’ Q3 2017 earnings at ($0.76) EPS, Q4 2017 earnings at ($0.82) EPS, FY2017 earnings at ($2.95) EPS, Q1 2018 earnings at ($0.76) EPS, Q2 2018 earnings at ($0.77) EPS, Q3 2018 earnings at ($0.65) EPS, Q4 2018 earnings at ($0.67) EPS, FY2018 earnings at ($2.84) EPS, FY2019 earnings at ($2.86) EPS, FY2020 earnings at ($3.20) EPS and FY2021 earnings at ($2.29) EPS.
Several other research firms have also recently commented on VYGR. Canaccord Genuity started coverage on shares of Voyager Therapeutics in a research report on Friday, October 27th. They issued a buy rating and a $35.00 price objective on the stock. Zacks Investment Research lowered shares of Voyager Therapeutics from a hold rating to a sell rating in a research note on Tuesday, October 17th. Stifel Nicolaus started coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They issued a buy rating and a $20.00 price target on the stock. ValuEngine upgraded shares of Voyager Therapeutics from a sell rating to a hold rating in a research note on Saturday, September 30th. Finally, BidaskClub upgraded shares of Voyager Therapeutics from a strong sell rating to a sell rating in a research note on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $28.89.
Voyager Therapeutics (NASDAQ:VYGR) traded down $3.58 on Tuesday, hitting $16.89. The stock had a trading volume of 927,177 shares, compared to its average volume of 456,415.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.11). The company had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative net margin of 1,195.63% and a negative return on equity of 60.63%. research analysts anticipate that Voyager Therapeutics will post -2.86 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/11/04/voyager-therapeutics-inc-vygr-given-positive-rating-at-wedbush.html.
In related news, insider Bernard Ravina sold 16,470 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.87, for a total value of $211,968.90. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 32,940 shares of company stock worth $490,092 over the last 90 days. 8.00% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Birchview Capital LP acquired a new position in Voyager Therapeutics in the 3rd quarter valued at about $494,000. Raymond James Financial Services Advisors Inc. acquired a new position in Voyager Therapeutics in the 3rd quarter valued at about $1,122,000. Nationwide Fund Advisors grew its stake in Voyager Therapeutics by 81.5% in the 3rd quarter. Nationwide Fund Advisors now owns 19,779 shares of the company’s stock valued at $407,000 after buying an additional 8,884 shares during the last quarter. California State Teachers Retirement System grew its stake in Voyager Therapeutics by 8.4% in the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after buying an additional 2,000 shares during the last quarter. Finally, State Street Corp grew its stake in Voyager Therapeutics by 11.8% in the 2nd quarter. State Street Corp now owns 184,526 shares of the company’s stock valued at $1,653,000 after buying an additional 19,471 shares during the last quarter. Institutional investors and hedge funds own 40.72% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
What are top analysts saying about Voyager Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Voyager Therapeutics Inc. and related companies.